Durgesh Kumar Dwivedi1, Tarun Javali2, Rajeev Kumar2, Sanjay Thulkar3, Sanjay Sharma3, Amit K. Dinda4, Naranamangalam R. Jagannathan1
1Department of NMR & MRI Facility, All India Institute of Medical Sciences, New Delhi, Delhi, India; 2Department of Urology, All India Institute of Medical Sciences, New Delhi, Delhi, India; 3Department of Radio-diagnosis, All India Institute of Medical Sciences, New Delhi, Delhi, India; 4Department of Pathology, All India Institute of Medical Sciences, New Delhi, Delhi, India
Raised serum prostate specific antigen (PSA) may not reflect the presence of prostate cancer (PCa) and transrectal ultrasound (TRUS) has limited sensitivity in PCa detection. MRSI has the potential to detect PCa based on metabolic differences. We performed a retrospective case controlled study on 278 men prior to biopsy with PSA in the range of 4-10 ng/ml. Our study revealed that MRSI directed TRUS biopsy increases PCa detection rate (2.9 times) compared to standard TRUS guided core (6 or 12) biopsy in patients with PSA in the range of 4-10 ng/ml.